Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2011

View Archived Issues

Merck & Co. presents new glucagon receptor antagonist for type 2 diabetes

Betulin shows potential for the treatment of metabolic syndrome

Bellicum granted award to support CaspaCIDe cancer therapy

New dual LFA-1/MAC-1 antagonists presented by Roche at the ACS meeting

Dainippon Sumitomo and Intercept sign licensing agreement for obeticholic acid

OriBase Pharma identifies agent for BCR/ABL T315I mutant CML

Cellzome patents new series of compounds that inhibit JAK3

SMO inhibitors reported by Pfizer for use in cancer

New steroid sulfatase/aromatase inhibitors reported by Sterix

Ark Therapeutics presents new neuropilin-1 antagonists

PHOENIX trial of PHP in distributive shock to continue after interim analysis

European Commission approves retigabine for partial onset seizures

ViroPharma begins phase II Cinryze study for antibody-mediated rejection

Gilead Sciences and Yale to collaborate on cancer research

Phase IIb trial of Pharmasset's PSI-7977 for multiple HCV genotypes begins

Phase II trial compares MDV-3100 with bicalutamide in advanced prostate cancer

Valeant Pharmaceuticals proposes to acquire Cephalon

Merck Serono applies for E.U. indication extension for Erbitux for advanced or metastatic NSCLC

Dainippon Sumitomo and Takeda sign agreement for lurasidone in Europe

Natco Pharma receives FDA orphan drug status for NRC-AN-019

Amgen and Takeda report topline phase II results for motesanib in lung cancer

U.S. Department of Defense and Cytos Biotechnology collaborate on malaria vaccines research

Eli Lilly launches Axiron topical testosterone replacement therapy in the U.S.

Alzheimer's Drug Discovery Foundation to fund Prana's PBT-2 phase II trial

Composite iMyD88/CD40 fusion protein shows enhanced antitumor activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...